Vizsgálati helyszín
Nanchang People's Hospital
Nanchang, Jiangxi 330009, KínaMég nincs intézményhez kötve
- 16futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis4 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Még nem toboroz5 vizsgálat
- Fut, nem toboroz2 vizsgálat
- Lezárult1 vizsgálat
- Fő szponzor
- Boehringer Ingelheim3 vizsgálat
- Pfizer2 vizsgálat
- Shanghai Junshi Bioscience Co., Ltd.2 vizsgálat
- BioNTech SE1 vizsgálat
- Celcuity Inc1 vizsgálat
- és még 8
Futó vizsgálatok
Toboroz
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
NCT07876557· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Wenyan Chen, Bachelor
Még nem toboroz
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257· 2. fázis· Sun Yat-sen University· Forrás
Contact: Wenyan Chen
Toboroz
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· 2/3. fázis· Hoffmann-La Roche· Forrás
Toboroz
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· 3. fázis· BioNTech SE· Forrás
Toboroz
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311· 2. fázis· Shanghai Junshi Bioscience Co., Ltd.· Forrás
Contact: Wenyan Chen, Doctor
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Toboroz
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· 3. fázis· Celcuity Inc· Forrás
Contact: Nadene Zack, MS
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029· 3. fázis· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Forrás
Contact: Yili Wang
Toboroz
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471· 3. fázis· Hasten Biopharmaceutical Co., Ltd.· Forrás
Contact: Zhaohui Pei
Toboroz
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
NCT06682195· 2. fázis· First Affiliated Hospital of Zhejiang University· Forrás
Contact: Yili Wang
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Toboroz
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· 3. fázis· Daiichi Sankyo· Forrás
Contact: Study Coordinator
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Chunwei Xie
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· 3. fázis· Gilead Sciences· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek